Eric Delbridge
InvestorGeneral Partner, Public Equity at Sofinnova Ventures
About
Eric Delbridge is a General Partner at Sofinnova Ventures, where he leads development of the firm's BioEquities strategy focused on public investments in global therapeutics companies. He joined Sofinnova in 2016 after managing market neutral therapeutics and healthcare portfolios at Balyasny Asset Management, and was previously a Partner at Spring Point Capital (formerly Botti Brown Asset Management) and a healthcare investment banker at Lazard and Credit Suisse. He holds an M.D. from Northwestern University, an M.B.A. from The Wharton School, and a B.A. in Classics from Yale University.
Invests in
Biotech
Colleagues at Sofinnova Ventures
Alex Chan
Controller, Private Equity at Sofinnova Ventures
Alex Dulnev
IT Manager at Sofinnova Ventures
Amanda Phillips
Executive Assistant at Sofinnova Ventures
Anastasia Voevodin
Analyst, Public Equity at Sofinnova Ventures
Aneal Tenjarla
Partner, Associate Portfolio Manager, Public Equity at Sofinnova Ventures
Calvin Sternick
Analyst, Public Equity at Sofinnova Ventures
Chris Carpenter
Executive Partner, Private Equity at Sofinnova Ventures
David Kabakoff
Executive Partner, Private Equity at Sofinnova Ventures
Frequently asked questions
- Who is Eric Delbridge?
- Eric Delbridge is a General Partner at Sofinnova Ventures, where he leads development of the firm's BioEquities strategy focused on public investments in global therapeutics companies. He joined Sofinnova in 2016 after managing market neutral therapeutics and healthcare portfolios at Balyasny Asset Management, and was previously a Partner at Spring Point Capital (formerly Botti Brown Asset Management) and a healthcare investment banker at Lazard and Credit Suisse. He holds an M.D. from Northwestern University, an M.B.A. from The Wharton School, and a B.A. in Classics from Yale University.
- Where does Eric Delbridge work?
- Eric Delbridge is General Partner, Public Equity at Sofinnova Ventures.
- What does Eric Delbridge invest in?
- Eric Delbridge invests in Biotech.